SEARCH

SEARCH BY CITATION

References

  • Andersson M., Terasmaa A., Fuxe K. and Stromberg I. (2005) Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia. J. Neurosci. Res. 82, 264272.
  • Blazquez C., Chiarlone A., Sagredo O. et al. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119136.
  • Blume L. C., Bass C. E., Dalton G. D., Selley D. E. and Howlett A. C. (2010) Cannabinoid receptor interacting protein (CRIP) 1a: signal transduction and epigenetic phenomena. ICRS Symp. Cannabinoids 20, P3P30.
  • Brady L. S., Herkenham M., Rothman R. B., Partilla J. S., Konig M., Zimmer A. M. and Zimmer A. (1999) Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. Brain Res. Mol. Brain Res. 68, 193197.
  • Cabral G. A. and Marciano-Cabral F. (2005) Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 78, 11921197.
  • Centonze D., Battista N., Rossi S., Mercuri N. B., Finazzi-Agro A., Bernardi G., Calabresi P. and Maccarrone M. (2004) A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 29, 14881497.
  • Crespo I., de Gomez H. and R. Rodriguez de F. F. and Navarro M. (2008) Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology 54, 219225.
  • Crunelle C. L., van de Giessen E., Schulz S., Vanderschuren L. J., de B. K., van den Brink W. and Booij J. (2011) Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. Addict. Biol. doi: 10.1111/j.1369-1600.2011.00369.x
  • De B. P., Heguy A., Hackett N. R., Ferris B., Leopold P. L., Lee J., Pierre L., Gao G., Wilson J. M. and Crystal R. G. (2006) High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol. Ther. 13, 6776.
  • Elphick M. R., Wallis K. T., Liu Y., Lewis D. L. and Egertova (2004) Localization of the CB1 cannabinoid receptor interacting protein (CRIP1a) in the brain. ICRS Symp. Cannabinoids 14, 19.
  • Fernandez-Ruiz J. (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 156, 10291040.
  • Fernandez-Ruiz J., Hernandez M. and Ramos J. A. (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e72e91.
  • Gao G. P., Alvira M. R., Wang L., Calcedo R., Johnston J. and Wilson J. M. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA 99, 1185411859.
  • Gerald T. M., Ward G. R., Howlett A. C. and Franklin S. O. (2006) CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression. Brain Res. 1093, 2024.
  • Gerdeman G. L., Ronesi J. and Lovinger D. M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5, 446451.
  • Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., Jr and Sibley D. R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 14291432.
  • Glass M. and Felder C. C. (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 53275333.
  • Glass M., Dragunow M. and Faull R. L. (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505519.
  • Herkenham M., Lynn A. B., De Costa B. R. and Richfield E. K. (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267274.
  • Hermann H., Marsicano G. and Lutz B. (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109, 451460.
  • Houchi H., Babovic D., Pierrefiche O., Ledent C., Daoust M. and Naassila M. (2005) CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30, 339349.
  • Hu S. S., Arnold A., Hutchens J. M., Radicke J., Cravatt B. F., Wager-Miller J., Mackie K. and Straiker A. (2010) Architecture of cannabinoid signaling in mouse retina. J. Comp. Neurol. 518, 38483866.
  • Ito D., Tanaka K., Suzuki S., Dembo T. and Fukuuchi Y. (2001) Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32, 12081215.
  • Jarrahian A., Watts V. J. and Barker E. L. (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 308, 880886.
  • Kearn C. S. (2004) Immunofluorescent mapping of cannabinoid CB1 and dopamine D2 receptors in the mouse brain. LI-COR Biosci, Application Notes.
  • Kearn C. S., Blake-Palmer K., Daniel E., Mackie K. and Glass M. (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 67, 16971704.
  • Kilkenny C., Browne W. J., Cuthill I. C., Emerson M. and Altman D. G. (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacother. 1, 9499.
  • Klein T. W., Newton C., Larsen K., Lu L., Perkins I., Nong L. and Friedman H. (2003) The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486496.
  • Lim G., Sung B., Ji R. R. and Mao J. (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212–2 on neuropathic pain behaviors in rats. Pain 105, 275283.
  • Lovinger D. M. (2010) Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 58, 951961.
  • Ludanyi A., Eross L., Czirjak S., Vajda J., Halasz P., Watanabe M., Palkovits M., Magloczky Z., Freund T. F. and Katona I. (2008) Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J. Neurosci. 28, 29762990.
  • Mackie K. (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol.. Vol. 168, 299325.
  • Mailleux P. and Vanderhaeghen J. J. (1992) Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci. Lett. 148, 173176.
  • Marcellino D., Carriba P., Filip M. et al. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. a combined neurochemical and behavioral analysis. Neuropharmacology 54, 815823.
  • Martin A. B., Fernandez-Espejo E., Ferrer B., Gorriti M. A., Bilbao A., Navarro M., de Rodriguez F. and F. and Moratalla R. (2008) Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33, 16671679.
  • Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U. and Freund T. F. (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137, 337361.
  • McBride J. L., Boudreau R. L., Harper S. Q. et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA 105, 58685873.
  • Meschler J. P. and Howlett A. C. (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40, 918926.
  • Niehaus J. L., Liu Y., Wallis K. T. et al. (2007) CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol. Pharmacol. 72, 15571566.
  • Paxinos G. and Watson C. (1997) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
  • Pickel V. M., Chan J., Kearn C. S. and Mackie K. (2006) Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J. Comp. Neurol. 495, 299313.
  • Przybyla J. A. and Watts V. J. (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J. Pharmacol. Exp. Ther. 332, 710719.
  • Sadri-Vakili G., Kumaresan V., Schmidt H. D. et al. (2010) Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine. J. Neurosci. 30, 1173511744.
  • Sanudo-Pena M. C., Tsou K. and Walker J. M. (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65, 703713.
  • Sheng W. S., Hu S., Min X., Cabral G. A., Lokensgard J. R. and Peterson P. K. (2005) Synthetic cannabinoid WIN55,212–2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211219.
  • Shi X. and McGinty J. F. (2006) Extracellular signal-regulated mitogen-activated protein kinase inhibitors decrease amphetamine-induced behavior and neuropeptide gene expression in the striatum. Neuroscience 138, 12891298.
  • Sim L. J., Selley D. E. and Childers S. R. (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc. Natl Acad. Sci. USA 92, 72427246.
  • Smith M. E. and Eng L. F. (1987) Glial fibrillary acidic protein in chronic relapsing experimental allergic encephalomyelitis in SJL/J mice. J. Neurosci. Res. 18, 203208.
  • Smith Y. and Villalba R. (2008) Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov. Disord. 23(Suppl 3), S534S547.
  • van der Stelt M. and DiMarzo V. (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480, 133150.
  • Szabo B., Dorner L., Pfreundtner C., Norenberg W. and Starke K. (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85, 395403.
  • Takeuchi Y., Miyamoto E. and Fukunaga K. (2002) Activation of the rat dopamine D2 receptor promoter by mitogen-activated protein kinase and Ca2+/calmodulin-dependent protein kinase II pathways. J. Neurochem. 83, 784796.
  • Tepper J. M., Abercrombie E. D. and Bolam J. P. (2007) Basal ganglia macrocircuits. Prog. Brain Res. 160, 37.
  • Thanos P. K., Gopez V., Delis F., Michaelides M., Grandy D. K., Wang G. J., Kunos G. and Volkow N. D. (2011) Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. Alcohol. Clin. Exp. Res. 35, 1927.
  • Van Waes V., Beverley J. A., Siman H., Tseng K. Y. and Steiner H. (2012) CB1 Cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation. Front. Pharmacol. 3, 21.
  • Warnault V., Houchi H., Barbier E., Pierrefiche O., Vilpoux C., Ledent C., Daoust M. and Naassila M. (2007) The lack of CB1 receptors prevents neuroadapatations of both NMDA and GABA(A) receptors after chronic ethanol exposure. J. Neurochem. 102, 741752.
  • Xiao X., Li J. and Samulski R. J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 22242232.